Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 39-48

  Kissow, Hannelouise ^a   Viby, Niels Erik ^a   Hartmann, Bolette ^a   Holst, Jens Juul ^a   Timm, Michael ^b   Thim, Lars ^c   Poulsen, Steen Seier ^a  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

5 Fluorouracil; Cancer; Immunohistochemistry; Proliferation

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; MYELOPEROXIDASE; NNC 103 0066; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME LOCALIZATION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE VILLUS; INTRACELLULAR TRANSPORT; MUCOSA INFLAMMATION; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; SMALL INTESTINE DISEASE; SMALL INTESTINE MUCOSA; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL PROLIFERATION; FEMALE; FLUOROURACIL; GLUCAGON-LIKE PEPTIDE 2; INTESTINE, SMALL; MUCOSITIS; PEROXIDASE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84863448504     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1882-2     Document Type: Article

References (29)

1. Duncan M, Grant G (2003) Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther 18(9):853-874 (Pubitemid 37346671)
2. Drucker DJ (2002) Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122(2):531-544
3. Drucker DJ, Erlich P, Asa SL et al (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93(15):7911-7916 (Pubitemid 26277138)
4. Tsai CH, Hill M, Asa SL et al (1997) Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 273(1 Pt 1):E77-E84
5. Chance WT, Foley-Nelson T, Thomas I et al (1997) Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 273(2 Pt 1):G559-G563
6. Drucker DJ (1998) Glucagon-like peptides. Diabetes 47(2):159-169
7. Benjamin MA, McKay DM, Yang PC et al (2000) Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47(1):112-119 (Pubitemid 30430419)
8. Booth C, Booth D, Williamson S et al (2004) Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 37(6):385-400 (Pubitemid 39577267)
9. Prasad R, Alavi K, Schwartz MZ (2000) Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 35(2):357-359 (Pubitemid 30082600)
10. Prasad R, Alavi K, Schwartz MZ (2001) GLP-2alpha accelerates recovery of mucosal absorptive function after intestinal ischemia/reperfusion. J Pediatr Surg 36(4):570-572 (Pubitemid 32268341)
11. Alavi K, Schwartz MZ, Palazzo JP et al (2000) Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 35(6):847-851 (Pubitemid 30346176)
12. Boushey RP, Yusta B, Drucker DJ (1999) Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277(5 Pt 1):E937-E947
13. Hartmann B, Johnsen AH, Orskov C et al (2000) Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 21(1):73-80 (Pubitemid 30126045)
14. Hartmann B, Thulesen J, Kissow H et al (2000) Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141(11):4013-4020
15. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330-338 (Pubitemid 37328853)
16. Xiao Q, Boushey RP, Cino M et al (2000) Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 278(4):R1057-R1063 (Pubitemid 30215220)
17. Schmidt PT, Ljung T, Hartmann B et al (2005) Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol 17(2):207-212 (Pubitemid 40349535)
18. Ghatei MA, Goodlad RA, Taheri S et al (2001) Proglucagon-derived peptides in intestinal epithelial proliferation: glucagonlike peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 46(6):1255-1263 (Pubitemid 32523272)
19. Nelson DW, Murali SG, Liu X et al (2008) Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. Am J Physiol Regul Integr Comp Physiol 294(4):R1175-R1184 (Pubitemid 351490636)
20. de Roy van Zuidewijn DBW, Schillings PHM, Wobbes T et al (1992) Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats. Exp Mol Pathol 56(2):96-107
21. Logan R, Stringer A, Bowen J et al (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63(2):239-251
22. Saegusa Y, Ichikawa T, Iwai T et al (2008) Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 43(1):59-65
23. Burrin DG, Stoll B, Jiang R et al (2000) GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 279(6):G1249-G1256
24. Shin ED, Estall JL, Izzo A et al (2005) Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128(5):1340-1353 (Pubitemid 40712184)
25. Boushey RP, Yusta B, Drucker DJ (2001) Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 61(2):687-693 (Pubitemid 32128634)
26. Yamazaki K, Yasuda N, Inoue T et al (2004) The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 488(1-3):213-218 (Pubitemid 38388541)
27. Tavakkolizadeh A, Shen R, Abraham P et al (2000) Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis. J Surg Res 91(1):77-82 (Pubitemid 30340900)
28. Thulesen J, Hartmann B, Hare KJ et al (2004) Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53(8):1145-1150 (Pubitemid 38961969)
29. Jeppesen PB, Gilroy R, Pertkiewicz M et al (2011) Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60(7):902-914